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Sir,
Global dissemination of carbapenemases among Gram-negative
bacteria is a growing public health concern. Therapeutic options
for these organisms are often limited, with alternative agents such
as tigecycline and colistin having potentially less favourable effi-
cacy and toxicity profiles.1,2 Furthermore, these agents are expen-
sive and not readily available in resource-constrained settings. In
the Lao People’s Democratic Republic (Laos), carbapenems are not
yet on the national list of essential drugs, although in Vientiane
the high prevalence of ESBL-producing Enterobacterales3,4 has
driven more widespread use of carbapenems imported by individ-
ual pharmacies from neighbouring countries. However, while
carbapenem-resistant Enterobacterales (CRE) and carbapenem-
resistant Acinetobacter baumannii (CRAB) have been described
in neighbouring Thailand and Vietnam,5 little is known about
carbapenem resistance in Laos, where few laboratories perform
antimicrobial susceptibility testing (AST) and surveillance networks
are notwell established.
The Microbiology Laboratory, Mahosot Hospital, Vientiane,
Laos, receives clinical samples from several hospitals in Vientiane
and other provinces, undertakes AST using CLSI methodology and
participates in the UK National External Quality Assessment (UK
NEQAS) scheme for AST. Since 2010, isolates of Enterobacterales
and Acinetobacter spp. displaying resistance to three or more first-
line agents have been routinely tested against meropenem using
10lg discs (Oxoid, Basingstoke, UK). In 2017, 280/428 Escherichia
coli, 67/208 Klebsiella pneumoniae and 35/111 Acinetobacter spp.
isolates underwent meropenem susceptibility testing. The first
carbapenem-resistant E. coli was identified in 2015. A second iso-
late (Patient 2)was sent to the Oxford Genomics Centre (University
of Oxford, Oxford, UK), where WGS using the Illumina HiSeq 2500
platform identified it as E. coli ST410 carrying blaNDM-5, prompting
the current review.
Laboratory records were retrospectively reviewed for merope-
nem- or imipenem-resistant Enterobacterales (from 1 January
2010 to 31 December 2017) and Acinetobacter spp. (from 1
January to 31 December 2017). All CRE and CRAB were retrieved
from storage at#80C and their identity was confirmed using API
20E for Enterobacterales and API 20NE for Acinetobacter spp.
(bioMe´rieux, Basingstoke, UK). Phenotypic susceptibilities were
confirmed by disc diffusion according to CLSI 2018 standards and
breakpoints,6 and the modified carbapenem inactivation method
(mCIM)6 was used to detect carbapenemase production. Clinical
and demographic data were obtained from review of hospital
charts. The isolates were sent for further characterization at PHE
(Colindale, London, UK), where they were tested for blaKPC, blaOXA-
48-like, blaNDM, blaVIM, blaIMP, blaSIM, blaGIM, blaSPM, blaFRI, blaIMI,
blaGES and blaSME carbapenemase genes and mcr-1/-2 acquired
colistin resistance genes using the AusDiagnosticsMT CRE EU assay
(AusDiagnostics, Chesham, UK).7 CRAB were also tested for blaOXA-
58-like, blaOXA-23-like, blaOXA-51-like and blaOXA-40-like carbapenemase
genes using a previously described OXA/class 1 integrase gene/
rpoBmultiplex PCR.8
Four CRE isolates, all E. coli, were identified from four patients
from two hospitals in Vientiane (1 from 2015, 1 from 2016 and 2
from 2017) (Table 1). Two were isolated from urine, one from a
wound swab, and one from a blood culture. All were resistant to
all b-lactams tested as well as to ciprofloxacin, gentamicin,
co-trimoxazole and tetracycline. Three isolates were susceptible to
amikacin, and both urinary isolates were also susceptible to fosfo-
mycin and nitrofurantoin, but the bloodstream isolate was only
susceptible to doxycycline and nitrofurantoin. None of the patients
had documented prior exposure to carbapenems. The mCIM test
confirmed carbapenemase production and molecular analysis
identified a New Delhi MBL (NDM) gene in all four isolates. NDM
subtypewas not determined.
Meropenem resistance was confirmed in 22 non-duplicate
Acinetobacter spp. isolates in 2017, all of which contained blaOXA-51-
like genes intrinsic to A. baumannii (Table S1, available as
Supplementary data at JACOnline). All isolateswere also resistant to
ceftriaxone, ceftazidime, imipenem, ciprofloxacin and tetracycline.
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Eighteen (81.8%) were susceptible to amikacin. Two isolates were
not susceptible to any agents tested. All CRAB produced theOXA-23-
like carbapenemase,with twoadditionally carrying anNDMcarbape-
nemase gene. Most CRAB (19/22) were from endotracheal aspirates
from the adult ICU atMahosot Hospital, but, as isolateswere not fur-
ther characterized, we could not determine whether this reflected
cross-infection in the ICU or the emergence of multiple independent
strains. Although colistin susceptibilitywasnot tested phenotypically,
mcr-1/-2geneswere not detected in either species.
To the best of our knowledge, this is the first report of
carbapenemase-producing E. coli and A. baumannii in Laos. While
our results are from a single laboratory and therefore may not be
representative of the epidemiology of carbapenem resistance na-
tionally, Mahosot Hospital is a tertiary referral centre from other
provinces and the Microbiology Laboratory also receives speci-
mens from hospitals in several provinces, comprising an informal
surveillance network. Molecular findings are consistent with
reports fromThailand andVietnam,where carbapenem resistance
inA. baumanniiandEnterobacterales appears to bepredominantly
related to OXA-23-like carbapenemases and NDM carbapene-
mases, respectively.5
In summary, this study demonstrates the presence of OXA-
23-like and NDM carbapenemases in Laos. Given the increasing
use of carbapenems, lack of established infection control
protocols, and limited access to alternative therapeutic agents in
Laos, this is of grave concern. Efforts to prevent further dissemin-
ation of these organisms in Laosmust be prioritized.
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